Abstract:ABSTRACT Objective The gut microbiota (GM) can have complicated and often undetermined interactions with the function of many organs in the body. GM is altered in a variety of liver diseases, but the significance of such changes on the liver disease is still unclear. Hepatic autophagy deficiency causes liver injury accompanied with cholestasis. Here, we investigated the impact of such hepatic changes on GM and in turn the effect of gut dysbiosis on liver injury. Design Fecal microbiota from mice with liver-specific loss of autophagy-related gene 5 ( Atg5), Atg5 Δhep mice, were analyzed by 16S sequencing. Antibiotics (ABX) was used to modulate GM in mice. Cholestyramine was used to reduce the enterohepatic bile acid (BA) level. The functional role of fibroblast growth factor 15 (FGF15) and ileal farnesoid X receptor (FXR) was examined in mice over-expressing FGF15 gene, or given a fibroblast growth factor receptor 4 (FGFR4) inhibitor. Results The composition of GM was significantly changed with a notable increase of BA-metabolizing bacteria in Atg5 Δhep mice, leading to a lower proportion of tauro-conjugated BAs and a higher proportion of unconjugated BAs in the intestine, which markedly activated ileal FXR with an increased expression of FGF15. ABX or cholestyramine treatment exacerbated liver injury and ductular reaction, and decreased FGF15 expression, whereas modulating FGF15 signaling altered liver phenotypes in the autophagy-deficient mice. Conclusion Gut dysbiosis can remedy liver injury in Atg5 Δhep mice through the FXR-FGF15 signaling. Antibiotics use in the condition of liver injury may have unexpected adverse consequences via the gut-liver axis. SHORT SUMMARY What is already known about this subject? Gut microbiota (GM) can be altered during hepatic pathogenesis. GM are involved in bile acid (BA) metabolism. Autophagy deficiency in the liver disrupts BA homeostasis and causes cholestatic injury. What are the new findings? Deficiency of autophagy in the liver causes alteration of GM, which leads to a higher proportion of BA-metabolizing bacteria. GM contribute to the activation of ileal farnesoid X receptor (FXR) and a higher expression of fibroblast growth factor 15 (FGF15) in autophagy deficient condition in the liver, which is associated with decreased levels of conjugated BAs and increased levels of unconjugated BAs in the intestine. Manipulations that lead to GM alteration, intestinal BA signaling, or FGF15 signaling can all modulate the liver phenotype. BA and GM together can act as a sensor to liver injury to trigger FGF15-mediated protective mechanism. How might it impact on clinical practice in the foreseeable future? These findings indicate that gut dysbiosis in the scenario of liver disease can be beneficial, suggesting cautions should be exercised in the use of antibiotics during specific liver diseases. If antibiotics need to be used in patients with liver diseases it may be beneficial to enhance the FXR-FGF15 feedback signaling to retain the protective effect of GM.

Role of gut/liver metabolites and gut microbiota in liver fibrosis caused by cholestasis

Gut microbial dysbiosis is associated with metabolism and immune factors in liver fibrosis mice

Bile acid-gut microbiota imbalance in cholestasis and its long-term effect in mice

Metabolomic Profiling for Histologically Fibrotic Stage in Chronic Drug-Induced Liver Injury

Pharmacodynamic Study of Chitosan in Combination with Salvianolic Acid B in the Treatment of CC14‐induced Liver Fibrosis in Mice

Intestinal microbiota drives cholestasis-induced specific hepatic gene expression patterns

Gut Microbial Dysbiosis Is Associated With Profibrotic Factors in Liver Fibrosis Mice.

Disorganized Gut Microbiome Contributed to Liver Cirrhosis Progression: A Meta-Omics-Based Study

Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury

Synergistic Inhibitory Effect of the Gut Microbiome and Lithocholic Acid on Liver Fibrosis

The gut microbiota–bile acid axis: A potential therapeutic target for liver fibrosis

Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism

Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis

Variation in the Gut Microbial Community is Associated with the Progression of Liver Regeneration

Alterations in the Gut Microbiota and Serum Metabolomics of Spontaneous Cholestasis Caused by Loss of FXR Signal in Mice

Dynamic Alterations of the Gut Microbial Pyrimidine and Purine Metabolism in the Development of Liver Cirrhosis

Metformin exerts anti-liver fibrosis effect based on the regulation of gut microbiota homeostasis and multi-target synergy

The Metabolomic Footprint of Liver Fibrosis

Gut Microbiota and Metabolomics Correlation in a Mouse Model of Acute-on-Chronic Liver Failure

Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease

Gut dysbiosis protects against liver injury in autophagy deficient mice by FXR-FGF15 feedback signaling